Asarfi Hospital

Asarfi Hospital reported Q4 FY26 consolidated revenue of 45.2 croreCurrent reported value: 45.2 crore. No comparable prior figure is available in the source record. (+29Current reported value: 29. No comparable prior figure is available in the source record.% YoY), EBITDA of 7.7 croreCurrent reported value: 7.7 crore. No comparable prior figure is available in the source record. (17Current reported value: 17. No comparable prior figure is available in the source record.% margin), and PAT of 3.9 croreCurrent reported value: 3.9 crore. No comparable prior figure is available in the source record. (+9Current reported value: 9. No comparable prior figure is available in the source record.% YoY). Full-year revenue grew 42% YoY to 173.5 croreCurrent 42% YoY to 173.5 crore. Reported change: N/A., with EBITDA margin at 20%. Growth was driven by higher IPD volumes (+46%Current 46%. Reported change: +46% YoY. YoY), improved case mix, and expansion of cardiac capacity to 45 beds. The cancer hospital scaled to 33 crore revenue (vs 20 crore last year) with 42% occupancy. Management guided for FY27 revenue of 260 croreCurrent reported value: 260 crore. No comparable prior figure is available in the source record. and EBITDA margin improvement to 22-23%, supported by bed expansion (cancer from 65 to 150 beds), bone marrow transplant unit, and potential inorganic growth. Key risks include regulatory delays in organ transplant approvals and volatility in government scheme reimbursements.